Home » Stocks » NVCR

Novocure Limited (NVCR)

Stock Price: $169.10 USD -2.74 (-1.59%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $168.80 -0.30 (-0.18%) Jan 22, 7:05 PM
Market Cap 17.21B
Revenue (ttm) 449.65M
Net Income (ttm) 19.15M
Shares Out 101.23M
EPS (ttm) 0.18
PE Ratio 919.02
Forward PE 333.33
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $169.10
Previous Close $171.84
Change ($) -2.74
Change (%) -1.59%
Day's Open 170.92
Day's Range 167.83 - 172.95
Day's Volume 263,331
52-Week Range 57.05 - 178.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 14 hours ago

A new paradigm in cancer treatment is developing

Seeking Alpha - 3 days ago

Shares of Novocure continue to trounce the overall markets return. The performance is justified as the company remains in the early innings of its growth ascendancy.

Zacks Investment Research - 1 week ago

Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.

Business Wire - 1 week ago

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.

Forbes - 3 weeks ago

After a stellar 3x rise since the March 23 levels of this year, at the current price of around $170 per share we believe Novocure stock, a company working on an innovative cancer treatment alt...

Business Wire - 1 month ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021.

Investors Business Daily - 1 month ago

Why Novocure, Leading Medical Devices Stock, Is One To Watch In 2021

Novocure is a medical devices company launched in 2000 to test a theory put forth by Yoram Palti, a professor of physiology and biophysics. Novocure that thinks of themselves as "sort of a hyb...

Business Wire - 1 month ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced national reimbursement in Switzerland for Optune in combination with temozolomide for the treatment of newly diagnosed GBM.

Business Wire - 1 month ago

ST. HELIER, Jersey--(BUSINESS WIRE)-- #btsm--Novocure announced the first patient has been enrolled in its global phase 3 TRIDENT trial.

Investors Business Daily - 1 month ago

Stock Market Analysis: Can Bulls Keep Running After A Big Week? Novocure, Intuitive Surgical Strong

Stock market analysis: Can bulls keep running after another big week? Novocure, Intuitive Surgical strong.

Other stocks mentioned: ISRG
Investors Business Daily - 1 month ago

Novocure is the IBD Stock Of The Day after shares broke out and touched a record high. Investor enthusiasm is frothing NVCR stock with several important studies due in 2021.

Investors Business Daily - 2 months ago

Dow At New High: Google, PayPal Flash Buy Signals; Novocure Tumbles

Dow Jones hits record high: Google, PayPal flash buy signals; Novocure tumbles. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, inv...

Other stocks mentioned: PYPL, GOOG, GOOGL
The Motley Fool - 2 months ago

The most likely culprit: profit-taking.

Investors Business Daily - 2 months ago

Rebounds from the 10-week line and breaking trend lines offer ways to start early positions in leaders. AMD, Twilio and Novocure offer both buy signals now.

Other stocks mentioned: AMD, TWLO, CRWD, OKTA
Investors Business Daily - 2 months ago

Stock market analysis; Novocure Flashes Several Buy Signals, Qorvo Sets Up New Entry

Stock market analysis; Novocure flashes several buy signals, Qorvo sets up new entry. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock list...

Other stocks mentioned: QRVO
Business Wire - 2 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting.

The Motley Fool - 2 months ago

These stocks might not get much attention, but they deserve yours.

Other stocks mentioned: FIVN, GNRC
Seeking Alpha - 2 months ago

Novocuore has disruptive technologies in cancer treatments. The company has enormous room for growth if management delivers.

Business Wire - 2 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure has received the CE mark for the NovoTTF-100L system, enabling commercialization of the device to treat MPM in the E.U. and Switzerland.

Business Wire - 2 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure's Research and Development Day will review two decades of Tumor Treating Fields research and introduce exciting new directions.

Business Wire - 2 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced the closing of a new $150 million revolving credit facility with a syndicate of relationship banks.

Business Wire - 2 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced the closing of $575 million 0% convertible senior notes private placement.

Investors Business Daily - 2 months ago

Novocure saw its IBD SmartSelect Composite Rating rise to 96 Wednesday, up from 94 the day before. The post Growing Novocure Sees Composite Rating Improve To 96 appeared first on Investor's Bu...

Business Wire - 2 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure prices $500 million 0% convertible senior notes through a private placement.

Business Wire - 2 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”).

Seeking Alpha - 2 months ago

Novocure Ltd (NVCR) CEO Asaf Danziger on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure reported financial results for the quarter ended September 30, 2020, and provided a company update.

Business Wire - 2 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced it has entered into a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology.

Zacks Investment Research - 2 months ago

Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-...

Other stocks mentioned: CHE, CRL, DVA, UHS
The Motley Fool - 2 months ago

In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.

Other stocks mentioned: NWBO
Zacks Investment Research - 3 months ago

Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.

Other stocks mentioned: LHCG, RMD
Zacks Investment Research - 3 months ago

Here are three growth stocks from the MedTech space which have maintained stellar performance even during the pandemic-led market meltdown.

Other stocks mentioned: LHCG, TMO
Zacks Investment Research - 3 months ago

Is (NVCR) Outperforming Other Medical Stocks This Year?

Business Wire - 3 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure will report financial results for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. financial markets open.

Business Wire - 3 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--The event on Nov. 12 will highlight progress across clinical and developmental pipelines and introduce areas of focus in translational research.

Business Wire - 3 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today initiatives to bring attention to Mesothelioma Awareness Day on September 26. In partnership with the Mesothelioma ...

Investors Business Daily - 4 months ago

Indexes Fade Strong Gains; Novocure, Brinker Hold Up

The Nasdaq held a modest gain in afternoon trading Wednesday after rising 1.6% intraday.

Other stocks mentioned: DRI, EAT
Investors Business Daily - 4 months ago

The IBD SmartSelect Composite Rating for Novocure increased from 94 to 96 Thursday. The post Top-Rated Stocks: Novocure Sees Composite Rating Climb To 96 appeared first on Investor's Business...

Business Wire - 4 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020.

Investors Business Daily - 4 months ago

Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.

Other stocks mentioned: EW, ISRG, BSX, GH
Business Wire - 5 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020.

Seeking Alpha - 5 months ago

NovoCure Limited (NVCR) CEO Asaf Danziger on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the quarter ended June 30, 2020, and provided a company update.

Forbes - 5 months ago

Have you missed out on the rally of these 5 stocks in the past three years? LivePerson, Novocure, Splunk, RingCentral and Teladoc?

Other stocks mentioned: LPSN, RNG, SPLK, TDOC
Business Wire - 5 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced today the recipients of the AACR-Novocure Grants for Tumor Treating Fields Research program.

Forbes - 5 months ago

The performance of the healthcare sector has been mixed this year. While dental and surgery-related stocks have declined - as Covid-19 impacts sectors that require a close person to person con...

Other stocks mentioned: ALXN, ACAD
Zacks Investment Research - 6 months ago

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 6 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)--The first patient has been enrolled in Novocure's EF-33 phase 2 pilot trial of Tumor Treating Fields delivered using high-intensity arrays.

Seeking Alpha - 6 months ago

This disruptive medtech player in oncology is up >7x since I started covering it on Seeking Alpha in 2016.

Business Wire - 6 months ago

ST. HELIER, Jersey--(BUSINESS WIRE)-- #LCSM--Novocure has entered into a clinical trial collaboration agreement with MSD to develop Tumor Treating Fields together with KEYTRUDA® for NSCLC.

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its product... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Oct 2, 2015
CEO
Asaf Danziger
Employees
782
Stock Exchange
NASDAQ
Ticker Symbol
NVCR
Full Company Profile

Financial Performance

In 2019, Novocure's revenue was $351.32 million, an increase of 41.62% compared to the previous year's $248.07 million. Losses were -$7.23 million, -88.62% less than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Novocure stock is "Hold." The 12-month stock price forecast is 136.00, which is a decrease of -19.57% from the latest price.

Price Target
$136.00
(-19.57% downside)
Analyst Consensus: Hold